Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Aptevo Therapeutics Inc. Director's Dealing 2018

Mar 6, 2018

35422_dirs_2018-03-05_75f2584a-da0e-4a66-b069-6de358482570.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Aptevo Therapeutics Inc. (APVO)
CIK: 0001671584
Period of Report: 2018-03-01

Reporting Person: Stromatt Scott C (Chief Medical Officer and SVP)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2018-03-01 Common Stock M 16269 Acquired 190845 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2018-03-01 Restricted Stock Unit $ M 16269 Disposed Common Stock (16269) Direct

Footnotes

F1: Each RSU converts into the Issuer's common stock on a one-for-one basis.

F2: The RSUs were originally issued by Emergent BioSolutions, Inc. ("Emergent") on March 1, 2016. As a result of the spin-off of the Issuer from Emergent effective on August 1, 2016 (the "Spin-off"), each RSU was adjusted and assumed by the Issuer. The RSUs vest in three equal annual installments on the anniversary of the grant date.